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INTRODUCTION
Heparin-induced thrombocytopenia (HIT) is an immune response-mediated severe adverse effect of anticoagulant therapy by unfractionated (UFH) or low-molecular weight heparin (LMWH). Major clinical symptoms of HIT are thrombocytopenia and thrombosis due to the generation of IgG isotype HIT antibodies that recognize platelet factor 4 (PF4) bound to heparin. It causes heparin-dependent platelet activation through cross-linking FcγIIa receptors leading to the release of prothrombotic platelet-derived microparticles (PMPs) with platelet consumption and severe thrombocytopenia (1, 2) . Due to the severity of HIT, early and accurate diagnosis is essential to initiate a proper treatment, i.e. the cessation of heparin with simultaneous application of an alternative anticoagulant therapy in order to reduce the risk of thrombosis, organ failure, amputation or death (3).
The laboratory evaluation for clinically suspected HIT should focus on the detection of heparin-dependent platelet activation induced by HIT antibodies (4) . Since testing is expensive and time-consuming, first the calculation of the 4T score based on four criteria (thrombocytopenia, timing of platelet count fall, thrombosis, and other causes for thrombocytopenia) needs to precede laboratory testing for HIT (5) . The 4T score system calculates the pretest probability of HIT, it has a high negative predictive value. HIT is unlikely in patients with a low pretest probability of HIT, however, suspected HIT has to be validated by laboratory tests.
Two types of laboratory approaches are used for the diagnosis of HIT: (i) immunoassays for the detection of antibodies against PF4-heparin complex, and (ii) functional assays to detect the platelet activating potential of HIT antibodies (6) . Immunoassays, especially the IgG specific solid-phase enzyme immunoassay (EIA), have a high negative predictive value, since negative antibody result excludes HIT (1, 7, 8) . Previous studies have suggested that the degree of positivity of the immunoassay should be taken into consideration: the higher the antibody titer, the higher the probability of thrombosis (9) (10) (11) .
In case of a positive immunoassay result, a functional test must be performed to detect the platelet activating HIT antibodies. The gold standard method for this assay is the serotonin release assay (SRA) that measures 14 C-serotonin released from activated 4 antibodies in the presence of therapeutic concentration of heparin activated healthy donor's platelet rich plasma and the translocation of phosphatidylserine to the surface of activated platelets could be observed by using fluorescently labeled Annexin V (14) . The elevated number of PMPs generated during platelet activation was also suggested as a surrogate marker for identifying HIT (15, 16) .
Since nowadays flow cytometers are usually available in larger clinical diagnostic laboratories we thought to take advantage of the detection of Annexin V positivity and PMP generation by activated platelets as a complementary approach to diagnose functional HIT antibodies. The aim of this study was to evaluate the performance of this flow cytometric functional assay in relation to the 4T score system, optical density (OD) results of EIA and the development of thrombosis. This way the study intended to provide additional data for the assessment of this functional assay in the diagnosis of HIT.
MATERIALS AND METHODS

Study design, Patients and Samples
Between January 2009 and December 2014 plasma samples of 405 patients with physician-suspected HIT were evaluated in order to confirm or exclude the clinical diagnosis.
HIT was suspected if there was a decrease in platelet count after the initiation of UFH or LMWH therapy in these hospitalized patients. We draw blood from healthy controls (n=4)
and from patients receiving heparin treatment without suspected HIT (n=4) in order to 
4T score
In order to calculate the 4T score value for patients, the clinical pathologist contacted the referring physician, and prior to the laboratory tests each patient was evaluated according to the four suggested criteria as published by Lo et al. to establish the clinical pretest probability of HIT (17) . Clinical 4T scores were grouped as follows: 0-3: low probability; 4-5: intermediate probability; 6-8: high probability of HIT.
Solid-phase enzyme immunoassay (EIA)
To detect the IgG isotype anti-PF4/heparin antibodies the commercially available 
Flow cytometric functional assay
The functional test was carried out in borderline patients (OD=0.3-0.5; n=11) and patients with positive EIA results (n=40). In order to validate the flow cytometric assay, the test was also carried out in 40 randomly chosen patients with negative EIA results in addition to the healthy controls (n=4) and patients receiving heparin treatment without suspected HIT (n=4).
6
The Annexin V-binding assay described by Tomer et al. (14) was performed with some minor modifications. Platelet rich plasma (PRP) was obtained from trisodium citrateanticoagulated blood of healthy donors having O blood type. To avoid donor platelet variation, during our tests PRP was obtained from the same selected high-responder donors as described previously (18) . Donor PRP was separated by centrifugation (150 g, 5 min, (i) at least 11% of platelets were Annexin V positive after treatment with 0.3 IU/mL heparin,
(ii) and the ratio of the percentage of Annexin V positive platelets generated in the presence of 0.3 IU/mL and that of 100 IU/mL of heparin was more than 1.5 (20) . PMPs produced by activated platelets were identified by size-selection based on their forward (FSC) and side scatter (SSC) properties. Latex spheres were used to test the correctness of PMP gating. The result of the PMP assay was expressed as the ratio between the number of PMPs generated at 0.3 IU/mL and 100 IU/mL of heparin. Positive result was considered when the PMP ratio was 1.5 or higher.
Statistical analysis
Mean values of the heparin-dependent EIA OD parameters of patient groups with either positive or negative Annexin V-binding functional assay results were compared by unpaired Student's t-test. Logistic regression analysis was used to estimate the effect of EIA OD units (continuous explanatory variable) on the outcome of the flow cytometric functional assays and on the risk of thrombosis (dichotomous dependent variables). Odds ratio with 95%
confidence intervals was calculated using STATA 9.0 software, a P value <0.05 was considered statistically significant.
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RESULTS
Patient characteristics and laboratory test results in HIT-suspected patients
HIT negative control plasma did not activate donor platelets, however, plasma sample of a HIT patient stimulated donor platelets in the presence of pharmacological heparin concentration (0.3 IU/mL). The fact that in the presence of excessive amount of heparin (100 IU/mL) platelets were not activated -or significantly less activated -proves the strict heparin concentration dependency of platelet activation (19) . The clinical and laboratory data of the 17 patients with positive Annexin V-binding functional assay results are shown in Table 1 .
The majority of the patients (n=11) were surgical cases, the remaining 6 patients were medical cases. Almost 2/3rd of these patients were female (64.7%), which was in agreement with a previous report (21) . In all 17 HIT patients, heparin administration was discontinued and 14 patients were switched to alternative anticoagulants (lepirudin or rivaroxaban). After the cessation of heparin treatment, platelet count recovered which was a clear indicator of HIT except for 3 patients who subsequently died. In Table 2 we summarized the clinical and laboratory data of EIA positive but functional test negative (n= 23) patients, including 10 medical and 13 surgical cases. Out of these 23 cases 18 patients were not treated with an alternative anticoagulant. Seven of these 18 patients died from causes other than thrombosis, their death were due to multiorgan failure, in 7 patients the platelet count recovered spontaneously. In the remaining 4 cases, platelet count did not recover, however thrombocytopenia had causes other than HIT. Five patients were given alternative anticoagulants, in 2 of them the platelet count remained low, in 3 cases (1 medical, 2 cardiac surgery cases) the platelet count recovered. The medical and one of the surgical patients had gastrointestinal bleeding and they died one month after the laboratory testing for HIT due to hypoxia and septicemia, respectively. It is to be noted that none of the Annexin V positive patients had low pretest probability of HIT based on their 4T score, their mean 4T score value was 5.71. The mean 4T score of EIA positive but functional assays negative patients was 4.22 while that of EIA negative patients was 3.63.
Association of heparin-dependent antibody level with functional test positivity
In patients with positive (n=40) and borderline (n=11) EIA results the functional assays were also carried out. First, the association between the IgG isotype EIA OD values with the outcome of the Annexin V-binding assay ( Fig. 2A ) and with that of PMP assay (Fig. 2B) were analyzed, only those patients are shown for whom both assay results are available (n=49). There were two Annexin V-binding positive cases in which negative results were obtained with the PMP assay ( Table 1 ). There was a positive association between the EIA OD values and the functional assay positivity: the higher the IgG isotype EIA OD value was measured, the higher the probability of a positive functional assay result was found.
In patients with a negative Annexin V-binding assay result and a positive EIA test (n=23) the average EIA OD value was 1.330. However, in those with positive functional assay results (n=17), the average EIA OD value was 2.544, which was significantly higher than the OD values in the former group (P<0.0001).
We used a logistic regression analysis to calculate the strength of the association between 
Association of heparin-dependent antibody level and functional test positivity with thrombosis
Since the most severe adverse event associated with HIT is thrombosis, we statistically analyzed the relationship between heparin-dependent antibody levels and the frequency of thrombotic events. Fig. 2C demonstrates that higher level of heparin-dependent antibody was associated with increased probability of thrombosis. Among subjects with positive EIA OD values (n=40) the overall rate of thrombotic events was 30% (12/40). The logistic regression analysis showed that the OD values of the EIA test were significantly associated with the presence of thrombosis in patients. The odds for having thrombosis was raised for each unit elevation in the OD value: OR: 3.05 (95%CI, 1.51-6.18; P= 0.002).
The positive flow cytometric assay results detecting platelet activation also showed a good agreement with the presence of thrombosis in our group of patients (Table 1 , Figs. 2A and   B ). 70.6% (12/17) of patients with both EIA and Annexin V test positivity showed thrombosis ( Table 1 ). The majority of PMP positive cases, 10 out of 14, also suffered from thrombosis.
Association of clinical pretest probability of HIT and functional test positivity
We also assessed the pretest probability of HIT by applying the 4T score system in our patient cohort. Based on these score values, EIA positive patients were classified as groups with low (n=5), intermediate (n=26) and high (n=9) pretest probability of HIT. In individuals with low pretest probability of HIT, the functional assay results were negative, showing that platelet activating antibodies were not present in these samples even in cases with high antibody titer (Fig. 3) . At intermediate pretest probability According to previous publications platelet activating antibodies are present in only one third to one half of EIA positive patients (1, 23, 24) . The actual value strongly depends on the patient population and the antibody class specificity of the EIA assay used for diagnosis. Our result is in good agreement with these data. The results suggest that the disease might be considerably over-diagnosed using only EIA assay without a functional test; EIA may detect non-platelet activating antibodies as well (22) . The PMP region analysis is a convenient flow assay to predict the platelet activating ability of the patient plasma, however, it proved to be somewhat less sensitive for predicting thrombosis at lower antibody OD values.
We carried out the laboratory investigation for all physician-suspected HIT patients, and the results supported the recommendation that in patients with a low pretest probability score (4T score ≤ 3) HIT could be confidently excluded without laboratory testing. None of our EIA positive patients with low 4T score had positive functional assay result and thrombosis in this large cohort of HIT suspected patients.
According to the literature 69% of the EIA and SRA positive patients suffered from thrombosis (25 The other washed platelet assay, HIPA is also a specific and sensitive test to detect clinically significant HIT antibodies. However, the appropriate donor platelet selection is essential for correct results in HIPA and the critically important washing steps also represent a crucial handling problem (27) . Indeed, in our preliminary experiments in a series of trisodium citrated samples, whole blood displayed 1.6% of mean platelet P-selectin positivity that became only slightly elevated in PRP (3.5%), but was significantly higher in washed platelets (30-41%) (data not shown). This means that washed platelets used for both SRA and HIPA became considerably activated already during the isolation procedures that may bias further functional responses.
The Annexin V-binding flow cytometric assay was shown to be an accurate test for the diagnosis of HIT. Previously Tomer then Poley and Mempel compared its sensitivity and specificity to these of the gold standard SRA and HIPA tests. The sensitivity of the flow cytometric assay was found to be 95% and 100% when it was compared to SRA and HIPA respectively, the specificity of the assay was 100% in both comparisons (14, 20) .
Even in early reports about the laboratory diagnosis of HIT the authors suggested that a flow cytometric assay can serve as a fast, accurate and cost effective test for this sometimes life-threating state, but as they described a special skill is needed to run a flow cytometer (20) .
Even in recent publications about the diagnosis of HIT, flow cytometry is described as one of the future possibilities (16, 18, 28) . In the past decade, flow cytometry has become an everyday practice in clinical laboratories by the introduction of novel compact size flow cytometers with user friendly softwares and it is gradually gaining space in confirming the 
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